Developer docs
API playgroundTry for free, no card

Search company profiles

CanariaBio

Full company profile

uuid00hj5sj

Namestring
CanariaBio
Legal namestring
Canariabio Inc.
Websiteurl
canariabio.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

CanariaBio (카나리아바이오, Canariabio Inc.) is a South Korea-based clinical-stage biopharmaceutical company focused on developing tumor antigen-specific monoclonal antibody immunotherapies for cancers with high unmet medical need. The company's core technology platform comprises a portfolio of monoclonal immunoglobulins targeting four tumor antigens — CA-125, MUC1, PSA, and Her2/neu — with two lead product candidates: Oregovomab, a first-in-class anti-CA-125 monoclonal antibody in global Phase III development (FLORA-5) for newly diagnosed and recurrent ovarian cancer, the deadliest gynecologic malignancy; and AR20.5 (BrevaRex), an anti-MUC1 monoclonal antibody that has completed Phase 1 for pancreatic cancer. The company previously listed on KOSDAQ (ticker 016790) in March 2022 and operates additional programs in FLORA-4 (Oregovomab + Niraparib combination Phase II) and FLORA-6 (Phase II).

The company's business model is pre-revenue: it generates no commercial product sales, has no distribution channels, and has not publicly disclosed pricing. Revenue mechanics, if/when Oregovomab is approved, would follow a traditional biopharmaceutical licensing/commercialization model, with regional partners already referenced (Specialised Therapeutics referenced via family-site links; co-development with Canada's OncoQuest). The company has experienced severe financial distress: in January 2024, the DSMB recommended discontinuation/monitoring of the Oregovomab Phase III trial, leading to capital impairment, a rejected 2023 audit opinion, and KOSDAQ trading suspension. In May 2024, the bio business was spun off into a new subsidiary, OcupeBio Inc. (오큐피바이오), with approximately KRW 267.6 billion in associated debt transferred, and a KRW 120 billion rights offering was launched in November 2024 to fund the continuation of FLORA-5. The company continues to operate through the listed entity and its biopharmaceutical subsidiary, with ongoing clinical follow-up monitoring of completed Oregovomab patients.

Short descriptiontext

CanariaBio is a South Korea-based, KOSDAQ-listed clinical-stage biopharmaceutical company developing first-in-class tumor antigen-specific monoclonal antibody immunotherapies, primarily Oregovomab for ovarian cancer and AR20.5 (BrevaRex) for pancreatic cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, monoclonal antibodies, ovarian cancer treatment, pancreatic cancer therapeutics, biopharmaceutical development
Industry1 code
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Cancer Immunotherapy Biopharmaceuticals
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Oregovomab
Description

First-in-class immunotherapy for ovarian cancer - flagship product undergoing global Phase III clinical trial

canariabio.com
+1 more record
Core offering1 text field

CanariaBio is a Korean biopharmaceutical company developing tumor antigen specific monoclonal antibody immunotherapies for cancers with high unmet medical needs. Its lead product, Oregovomab, is a first-in-class monoclonal antibody targeting CA-125 for ovarian cancer and is in global Phase III clinical trials. A second pipeline candidate, AR20.5 (BrevaRex), targets MUC1 for pancreatic cancer treatment and is in Phase 1/2 development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CanariaBio is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. The company's portfolio includes Oregovomab as the flagship first-in-class ovarian cancer immunotherapy product undergoing global Phase III trials, and AR20.5 (BrevaRex) targeting pancreatic cancer in Phase 1/2 development. These are supported by a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu antigens.

Product and service2 records
1Oregovomab
CategoryCancer Immunotherapy
Description

First-in-class monoclonal antibody immunotherapy targeting CA-125 tumor antigen for ovarian cancer. Designed for patients with newly diagnosed and recurrent ovarian cancer. Currently in global Phase III clinical trials (FLORA-5) conducted at 163 sites across 16 countries.

2BrevaRex (MAb-AR20.5)
CategoryCancer Immunotherapy
Description

Monoclonal antibody targeting MUC1 for pancreatic cancer treatment. Phase 1 completed with Phase 2 planned. Addresses pancreatic cancer, which accounts for approximately 7% of all cancer deaths.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1OncoQuest (Canada)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Canadian biotech company that led the successful Phase II clinical trial. OncoQuest clinical team is leading the review of Phase III continuation decisions following DSMB recommendations. Partnership involves co-development of Oregovomab immunotherapy for ovarian cancer.

canariabio.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing monoclonal antibody-based therapeutics for cancer, including programs targeting solid tumors — directly comparable as a focused oncology mAb developer with platform technology.

2OncoQuest (Canada)
TypeEmerging player
Description

Canadian biotech that led the Phase II trial of Oregovomab and is the strategic co-development partner for the Phase III program; directly comparable as a clinical-stage oncology mAb developer and CanariasBio's closest operational peer.

3Bristol-Myers Squibb
TypeBroad incumbent
Description

Major immuno-oncology player with Opdivo (nivolumab) and Yervoy (ipilimumab); comparable as a developer of monoclonal antibody-based cancer immunotherapy across multiple solid tumor indications.

TypeDirect peer
Description

Developed Rubraca (rucaparib) for ovarian cancer; comparable as a focused ovarian cancer therapeutics developer that experienced commercial and clinical setbacks — relevant cautionary parallel.

TypeBroad incumbent
Description

Major oncology incumbent with Lynparza (olaparib) as a leading ovarian cancer therapy and a broad immuno-oncology pipeline; comparable as a competitor in ovarian cancer treatment and a developer of biologic cancer therapeutics.

TypeDirect peer
Description

Developed mirvetuximab soravtansine, a first-in-class FRα-targeted antibody-drug conjugate for ovarian cancer — the most directly comparable antibody-based ovarian cancer therapeutic developer, recently acquired by AbbVie.

TypeBroad incumbent
Description

Leader in immuno-oncology with Keytruda (pembrolizumab); comparable as a developer and commercializer of cancer immunotherapy including ovarian cancer indications where PD-1/PD-L1 mechanisms compete with novel mAb approaches.

TypeBroad incumbent
Description

Major oncology player with ovarian cancer therapy Zejula (niraparib) and a growing immuno-oncology pipeline; comparable as a competitor in ovarian cancer treatment and as a developer of antibody-based cancer therapeutics.

TypeBroad incumbent
Description

Pioneer and global leader in monoclonal antibody therapeutics for oncology, including Her2/neu-targeted agents (Herceptin) that overlap with CanariasBio's platform targets — comparable as both a direct and adjacent competitor in mAb cancer therapy.

TypeRegional player
Description

Listed as a family-site partner on CanariasBio's website, indicating a regional distribution/co-development relationship for Oregovomab; comparable as a specialty oncology partner with geographic overlap in Asian/Pacific markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CanariaBio

Cancer Immunotherapy Biopharmaceuticalscanariabio.com

CanariaBio is a South Korea-based, KOSDAQ-listed clinical-stage biopharmaceutical company developing first-in-class tumor antigen-specific monoclonal antibody immunotherapies, primarily Oregovomab for ovarian cancer and AR20.5 (BrevaRex) for pancreatic cancer.

What CanariaBio does

CanariaBio (카나리아바이오, Canariabio Inc.) is a South Korea-based clinical-stage biopharmaceutical company focused on developing tumor antigen-specific monoclonal antibody immunotherapies for cancers with high unmet medical need. The company's core technology platform comprises a portfolio of monoclonal immunoglobulins targeting four tumor antigens — CA-125, MUC1, PSA, and Her2/neu — with two lead product candidates: Oregovomab, a first-in-class anti-CA-125 monoclonal antibody in global Phase III development (FLORA-5) for newly diagnosed and recurrent ovarian cancer, the deadliest gynecologic malignancy; and AR20.5 (BrevaRex), an anti-MUC1 monoclonal antibody that has completed Phase 1 for pancreatic cancer. The company previously listed on KOSDAQ (ticker 016790) in March 2022 and operates additional programs in FLORA-4 (Oregovomab + Niraparib combination Phase II) and FLORA-6 (Phase II).

The company's business model is pre-revenue: it generates no commercial product sales, has no distribution channels, and has not publicly disclosed pricing. Revenue mechanics, if/when Oregovomab is approved, would follow a traditional biopharmaceutical licensing/commercialization model, with regional partners already referenced (Specialised Therapeutics referenced via family-site links; co-development with Canada's OncoQuest). The company has experienced severe financial distress: in January 2024, the DSMB recommended discontinuation/monitoring of the Oregovomab Phase III trial, leading to capital impairment, a rejected 2023 audit opinion, and KOSDAQ trading suspension. In May 2024, the bio business was spun off into a new subsidiary, OcupeBio Inc. (오큐피바이오), with approximately KRW 267.6 billion in associated debt transferred, and a KRW 120 billion rights offering was launched in November 2024 to fund the continuation of FLORA-5. The company continues to operate through the listed entity and its biopharmaceutical subsidiary, with ongoing clinical follow-up monitoring of completed Oregovomab patients.

CanariaBio firmographics

Firmographics
Name
CanariaBio
Legal name
Canariabio Inc.
Website
https://canariabio.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
CanariaBio is a South Korea-based, KOSDAQ-listed clinical-stage biopharmaceutical company developing first-in-class tumor antigen-specific monoclonal antibody immunotherapies, primarily Oregovomab for ovarian cancer and AR20.5 (BrevaRex) for pancreatic cancer.
Ownership category
akta.pro rank

CanariaBio industry classification

Industry
Product category
Cancer Immunotherapy Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cancer immunotherapy
  • Monoclonal antibodies
  • Ovarian cancer treatment
  • Pancreatic cancer therapeutics
  • Biopharmaceutical development

Where CanariaBio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

CanariaBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Marketing channels3 records

CanariaBio product offering

Product offering

Core offering

CanariaBio is a Korean biopharmaceutical company developing tumor antigen specific monoclonal antibody immunotherapies for cancers with high unmet medical needs. Its lead product, Oregovomab, is a first-in-class monoclonal antibody targeting CA-125 for ovarian cancer and is in global Phase III clinical trials. A second pipeline candidate, AR20.5 (BrevaRex), targets MUC1 for pancreatic cancer treatment and is in Phase 1/2 development.

Product overview

CanariaBio is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. The company's portfolio includes Oregovomab as the flagship first-in-class ovarian cancer immunotherapy product undergoing global Phase III trials, and AR20.5 (BrevaRex) targeting pancreatic cancer in Phase 1/2 development. These are supported by a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu antigens.

Differentiator

Problem solved

Functional benefit

Brands

  • Oregovomab: First-in-class immunotherapy for ovarian cancer - flagship product undergoing global Phase III clinical trial
  • BrevaRex (MAb-AR20.5)

Products and services

  • Oregovomab First-in-class monoclonal antibody immunotherapy targeting CA-125 tumor antigen for ovarian cancer. Designed for patients with newly diagnosed and recurrent ovarian cancer. Currently in global Phase III clinical trials (FLORA-5) conducted at 163 sites across 16 countries.
  • BrevaRex (MAb-AR20.5) Monoclonal antibody targeting MUC1 for pancreatic cancer treatment. Phase 1 completed with Phase 2 planned. Addresses pancreatic cancer, which accounts for approximately 7% of all cancer deaths.

Companies that use CanariaBio

Customer profile

Segments1 record

Ideal customer profiles2 records

CanariaBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CanariaBio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • OncoQuest (Canada)coreStrategic or Co-development Partner · 17 January 2024Canadian biotech company that led the successful Phase II clinical trial. OncoQuest clinical team is leading the review of Phase III continuation decisions following DSMB recommendations. Partnership involves co-development of Oregovomab immunotherapy for ovarian cancer.

Scale indicators5 records

Recent moves12 records

Expansion highlights6 records

CanariaBio competitors and assessment

Company assessment

Direct peers

  • MacroGenics: Clinical-stage biotechnology company developing monoclonal antibody-based therapeutics for cancer, including programs targeting solid tumors — directly comparable as a focused oncology mAb developer with platform technology.
  • Clovis Oncology: Developed Rubraca (rucaparib) for ovarian cancer; comparable as a focused ovarian cancer therapeutics developer that experienced commercial and clinical setbacks — relevant cautionary parallel.
  • ImmunoGen: Developed mirvetuximab soravtansine, a first-in-class FRα-targeted antibody-drug conjugate for ovarian cancer — the most directly comparable antibody-based ovarian cancer therapeutic developer, recently acquired by AbbVie.

Emerging players

  • OncoQuest (Canada): Canadian biotech that led the Phase II trial of Oregovomab and is the strategic co-development partner for the Phase III program; directly comparable as a clinical-stage oncology mAb developer and CanariasBio's closest operational peer.

Broad incumbents

  • Bristol-Myers Squibb: Major immuno-oncology player with Opdivo (nivolumab) and Yervoy (ipilimumab); comparable as a developer of monoclonal antibody-based cancer immunotherapy across multiple solid tumor indications.
  • AstraZeneca: Major oncology incumbent with Lynparza (olaparib) as a leading ovarian cancer therapy and a broad immuno-oncology pipeline; comparable as a competitor in ovarian cancer treatment and a developer of biologic cancer therapeutics.
  • Merck & Co. Leader in immuno-oncology with Keytruda (pembrolizumab); comparable as a developer and commercializer of cancer immunotherapy including ovarian cancer indications where PD-1/PD-L1 mechanisms compete with novel mAb approaches.
  • GSK: Major oncology player with ovarian cancer therapy Zejula (niraparib) and a growing immuno-oncology pipeline; comparable as a competitor in ovarian cancer treatment and as a developer of antibody-based cancer therapeutics.
  • Genentech (Roche): Pioneer and global leader in monoclonal antibody therapeutics for oncology, including Her2/neu-targeted agents (Herceptin) that overlap with CanariasBio's platform targets — comparable as both a direct and adjacent competitor in mAb cancer therapy.

Regional players

  • Specialised Therapeutics: Listed as a family-site partner on CanariasBio's website, indicating a regional distribution/co-development relationship for Oregovomab; comparable as a specialty oncology partner with geographic overlap in Asian/Pacific markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

CanariaBio social profiles

Digital presence

CanariaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CanariaBio leadership team

Management profile

Number of profiles

Profiles1 record

CanariaBio subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

CanariaBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CanariaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanariaBio

What does CanariaBio do?

CanariaBio is a Korean biopharmaceutical company developing tumor antigen specific monoclonal antibody immunotherapies for cancers with high unmet medical needs. Its lead product, Oregovomab, is a first-in-class monoclonal antibody targeting CA-125 for ovarian cancer and is in global Phase III clinical trials. A second pipeline candidate, AR20.5 (BrevaRex), targets MUC1 for pancreatic cancer treatment and is in Phase 1/2 development.

Is CanariaBio a public or private company?

CanariaBio is a public company. It is classified as public and is currently operating.

When was CanariaBio founded?

CanariaBio was founded in 2000. It employs 11 to 50 people.

Where is CanariaBio based?

CanariaBio is headquartered in Seoul, South Korea, in the Asia region.

Who are CanariaBio's main competitors?

Direct peers on record are MacroGenics, Clovis Oncology and ImmunoGen. OncoQuest (Canada) is listed as an emerging player. Broad incumbents are Bristol-Myers Squibb, AstraZeneca, Merck & Co., GSK and Genentech (Roche). Specialised Therapeutics is listed as a regional player.

Does CanariaBio have an API?

No public API is recorded for CanariaBio.

What industry is CanariaBio in?

CanariaBio's product category is Cancer Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooSpackman Equities Issues Corrective Disclosure and Announces Termination of Advisory Agreement with CanariaBio Inc.Spackman Equities Group Inc. issued a corrective disclosure following a review by the Ontario Securities Commission, addressing prior omissions in its financial reports and expanding on its business operations and governance. The company updated disclosures related to its advisory agreement with CanariaBio Inc. and its reverse takeover transaction with Crystal Planet Limited.FinanzNachrichten.deSpackman Equities Group Inc.: Spackman Equities Issues Corrective Disclosure and Announces Termination of Advisory Agreement with CanariaBio Inc.Spackman Equities Group Inc. (TSXV: SQG) has issued a corrective disclosure following a continuous disclosure review by the Ontario Securities Commission, which identified deficiencies in the company's interim financial statements for the first three quarters of fiscal 2025, including inadequate disclosure of business activities, risk factors, governance, and related party transactions. The company also confirmed that financial statements for Crystal Planet Limited, the target of a proposed reverse takeover, were not filed within the required period under NI 51-102, and the advisory agreement with CanariaBio Inc. was terminated on May 22, 2026. As a result of these compliance failures, Spackman Equities will be placed on the OSC's public list of Refiling and Errors for three years.AETOSWireHikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North AfricaHikma Pharmaceuticals signed an exclusive licensing agreement with CanariaBio to commercialize Oregovomab in 18 Middle East and North Africa countries. Oregovomab is a first-in-class anti-CA125 immunotherapy for advanced ovarian cancer, holding orphan drug designations from the FDA and EMA.PR NewswireCanariaBio gibt das Erreichen eines Meilensteins bekannt: 50 % der Patientinnen werden in die klinische Phase-III-Studie FLORA-5 für das Hauptprodukt Oregovomab zur Erstbehandlung von fortgeschritteneCanariaBio Inc. announced that it has reached 50% of its target patient recruitment for the Phase III FLORA-5 clinical trial of Oregovomab for advanced ovarian cancer. The multinational study, currently enrolling patients across more than 137 centers in countries including the USA, South Korea, and Brazil, involves combining Oregovomab with standard chemotherapy. An independent data safety monitoring board recommended continuing the study without changes following a review in March 2022.PR NewswireCanariaBio annonce avoir franchi l'étape importante du recrutement de 50 % des patients dans son étude clinique de phase III FLORA-5 sur son produit phare, l'orégovomab, destiné au traitement en premiCanariaBio Inc., a Korean biopharmaceutical company, announced it has reached 50% enrollment — 301 of 602 planned patients — for its Phase III FLORA-5 clinical trial of oregovomab, an IgG monoclonal antibody, in combination with standard chemotherapy (carboplatine and paclitaxel) for first-line treatment of advanced ovarian cancer. The multinational, double-blind, placebo-controlled trial is actively recruiting across more than 137 clinical centers in 14 countries, with additional sites opening in India and Romania, and the Independent Data Safety Monitoring Board found no safety concerns at its March 2022 review. A prior Phase II trial showed the oregovomab-based regimen reduced the risk of progression and death by over 50% compared to chemotherapy alone, without added toxicity.PR NewswireCanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatmentCanariaBio Inc. announced it has reached 50% enrollment (301 of 602 target patients) in its pivotal Phase III FLORA-5 clinical trial evaluating oregovomab in combination with standard chemotherapy for front-line advanced ovarian cancer treatment. The multinational, double-blind, placebo-controlled trial is currently accruing patients at over 137 centers across 16 countries including the US, Canada, Brazil, and several European nations. The last Independent Data Safety Monitoring Board review in March 2022 identified no safety concerns and recommended continuation of the study, with Phase 2 data previously demonstrating a greater than 50% reduction in risk of progression and death compared to standard chemotherapy alone.